Cardiovascular

Long Term Outcomes of Drug Eluting and Bare Metal Stents in Patients Undergoing PCI

Laura Mauri
Laura Mauri
Raymond Gibbons
Raymond Gibbons

REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
LAURA MAURI, Brigham and Woman’s Hospital, Boston Massachusetts
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester, Minnesota

The largest study to date looking at long-term outcomes of bare metal stents as compared with drug eluting stents in patients who have undergone PCI was presented to the American Heart Association annual meeting. There was no increased mortality for patients who received drug eluting stents in a Massachussets based population. Sarah Maxwell spoke with investigator to Laura Mauri at the Orlando meeting.

Similar Interviews

  • Audio Journal of Medicine: Drug Eluting Stents, Bare Metal Stents: No Survival Difference">Audio Journal of Medicine: Drug Eluting Stents, Bare Metal Stents: No Survival Difference
  • Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006">Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006
  • Joseph Muhlestein

  • TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?
  • Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida

    Post a comment

    Subscribe to Audio Medica Podcast